About Index pharmaceuticals ab
InDex Pharmaceuticals AB is a Swedish biopharmaceutical company that specializes in the development of immunomodulatory drugs for the treatment of inflammatory diseases. The company was founded in 2000 and has since then been dedicated to developing innovative therapies that can improve the lives of patients suffering from chronic inflammatory conditions.
InDex Pharmaceuticals Holding AB (publ) is the parent company of InDex Pharmaceuticals AB and InDex Diagnostics AB, which are both wholly-owned subsidiaries. The Group's focus is on developing new treatments for inflammatory bowel disease (IBD), a group of chronic disorders that affect millions of people worldwide.
The company's lead product candidate, cobitolimod, is a novel Toll-like receptor 9 (TLR9) agonist designed to treat moderate to severe ulcerative colitis (UC). Cobitolimod works by activating TLR9 receptors on immune cells in the gut, which helps to reduce inflammation and promote healing. Clinical trials have shown promising results for cobitolimod, with significant improvements observed in patients' symptoms and quality of life.
In addition to cobitolimod, InDex Pharmaceuticals has several other drug candidates in its pipeline. These include Kappaproct®, an immunomodulatory peptide designed to treat severe UC; DIMS0150, an oral formulation of cobitolimod; and IND-47, a novel inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4) currently being developed for IBD.
The company's research efforts are supported by a team of experienced scientists and clinicians who are dedicated to advancing our understanding of IBD pathogenesis and developing new therapies that can address unmet medical needs. In addition to its internal R&D programs, InDex Pharmaceuticals also collaborates with academic institutions and industry partners around the world to accelerate drug discovery efforts.
At Index pharmaceuticals ab we believe that our commitment towards developing innovative therapies for IBD will help us to make a significant impact on the lives of patients suffering from these debilitating conditions. Our goal is to become a leading player in the field of immunomodulatory drugs and to continue advancing our pipeline of novel drug candidates. We are confident that with our strong scientific expertise, dedicated team, and cutting-edge technology, we can achieve this goal and improve the lives of millions of people worldwide.